BioSpace News Archive

Albireo Pharma, Inc. (Nasdaq: ALBO), a rare pediatric liver disease company developing novel bile acid modulators, today announced that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorization for Bylvay (odevixibat) for the treatment of all types of progressive familial intrahepatic cholestasis (PFIC).

Brickell Biotech, Inc. today announced that it is scheduled to participate in two upcoming virtual investment conferences, including the H.C. Wainwright 23rd Annual Global Investment Conference

Wave Life Sciences Ltd. today announced it will highlight its ADAR-mediated RNA editing capability at its 2021 Analyst and Investor Research Webcast taking place Tuesday, September 28, 2021 at 10:00 a.m. EDT.

Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that its collaboration to develop treatments for epilepsy with Neurocrine Biosciences, Inc. (Nasdaq: NBIX) achieved a regulatory milestone with the approval of a clinical trial application (CTA) in Europe, triggering an aggregate payment of $10.0 million to Xenon.

Coherus BioSciences, Inc. today announced upcoming medical conference presentations. Toripalimab clinical data will be presented September 13 at the IASLC 2021 World Conference on Lung Cancer and September 17 at the European Society for Medical Oncology Congress 2021.

Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, , today announced it will exhibit at the Heart Failure Society of America (HFSA) Annual Scientific Meeting (ASM) 2021 – which brings together the world’s leading experts in heart failure from September 10-13, 2021.

Anixa Biosciences, Inc. announced today that Dr. Amit Kumar , Anixa’s Chief Executive Officer, will present at the virtual H.C. Wainwright 23rd Annual Global Investment Conference being held September 13-15 , 2021.

Lab managers, technology leaders and principal scientists in pharmaceutical, food and environmental laboratories can now benefit from accelerated throughput and improved sensitivity to meet rapidly changing regulatory requirements and provide the fast responses needed for tackling emerging human and environmental health risks.

Principal investigators, laboratories, and proteomics researchers in academia, biopharma and contract research organizations can now benefit from an all-in-one nano-, capillary- and micro-flow liquid chromatography system.

Frontage Shanghai announced the acquisition of 70% equity interest in Wuhan Heyan Biomedical Technology Co., Ltd.